---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020313"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T12:34:41.495194+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel reports 2024 net income $17.5M, record product sales $144.9M, guides FY25 rev $200-210M

## Summary
- 4Q total revenue $57.6M; TAVALISSE $31.0M (+21% YoY), REZLIDHIA $7.4M (+92% YoY), GAVRETO $8.1M.
- FY24 total revenue $179.3M; net product sales $144.9M (+39% YoY); net income $17.5M vs loss $25.1M in FY23.
- Cash & short-term investments $77.3M at year-end, up from $56.9M; expects positive net income in FY25.
- FY25 guidance: total revenue $200-210M; net product sales $185-192M; contract revenues $15-18M.
- R289 granted Fast Track and Orphan Drug designations for MDS; partner TAVALISSE approvals in South Korea and Mexico.

## SEC filing metadata
- accession: 0001104659-25-020313
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/0001104659-25-020313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/tm258144d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020313
- JSON: https://secwatch.observer/filing/0001104659-25-020313.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.